Author: Kathrynne HoldenPublished: 26 January 2017
Prep: -Cook: -Serves: -
In her latest nutrition article, former National Parkinson Foundation dietician Kathrynne Holden, explains the benefits of vitamin B3 – also known as niacin – for people with young-onset Parkinson’s
Vitamin B3, or niacin, is one of the vitamins needed for human life. While it is necessary for everyone, it may have added value for people with inherited Parkinson’s disease.
In a recent research study from the University of Leicester, scientists examined the effect of niacin-rich foods on fruit flies. The flies had a genetic mutation similar to the one in people with hereditary Parkinson’s disease. They learned that the high-niacin food prevented the degeneration of neurons in the brains of the flies.
What does this mean for people with Parkinson’s disease?
We can’t assume that an animal study will apply to humans. About 75% of the DNA in fruit flies is the same as human DNA, so although flies are good research subjects, the study results are not conclusive.
However, it is still possible that niacin-rich foods could benefit people with Parkinson’s disease. As niacin is already being used in cancer studies, and in treating strokes, we can trust that increasing high-niacin foods in our diet will be safe, and may be therapeutic. It is important to note that the research indicates that natural, food-based sources of niacin/vitamin B3 are preferable, rather than supplement tablets.
How much niacin/vitamin B3 do we need daily?
The recommended daily amount (RDA) of vitamin B3 for adults is 16mg for men and 14mg for women. There is no risk of excess or toxicity from foods. However, with use of supplement tablets there is an upper limit of 35mg per day for adults. Very high doses of supplements can cause a burning sensation in the skin of the face and chest, and can increase histamine in people with allergies. Another factor to be aware of is that some people with Parkinson’s disease have orthostatic hypotension (low blood pressure) and vitamin B3 supplements can cause a dangerous drop in blood pressure.
Which foods are high in vitamin B3?
High-protein foods are the richest in vitamin B3. We must consider that people using levodopa may be sensitive to protein, and, if so, will need to carefully time medications and meals, so that the levodopa is absorbed into the bloodstream ahead of protein in the meal.
By combining servings of high-protein foods with grains, vegetables, pulses and fruits you can be certain to get plenty of vitamin B3 in your daily menu. Below is a one-day meal plan that’s high in vitamin B3.
Morning meal 1 cup cooked barley cereal with milk or milk alternative 3.2mg
1 slice whole wheat bread, toasted with butter 1.3mg
1 banana 0.67mg
Juice, milk, coffee or tea as desired
Midday meal Tuna sandwich
(with canned tuna and two slices whole wheat bread 9.6mg
Coleslaw or lettuce salad
Beverage of choice
The day’s menu exceeds the RDA for both men and women, yet is well below the upper limit of 35mg. Whether you are living with Parkinson’s or not, this is a healthy day’s menu, with a variety of foods, and ample vitamin B3.
‘Shakshuka’ is a dish of eggs poached in a sauce of tomatoes, chili peppers and onions
Podcast: Women and Parkinson’s disease – the research gap
Addressing the “lack of information” on women and the condition
5 months ago
35 new Parkinson’s drug trials launched in last year
Researchers launched 35 new clinical trials of Parkinson’s drug therapies in the last year, according to recent findings published in the ‘Journal of Parkinson’s Disease’. The 2023 Parkinson’s drug development pipeline report noted a slight decrease in active trials compared to the 2022 update (down from 147 to 139 overall). About one-third of trials were still in Phase 1, half were in Phase 2 – and just 20 (14%) were in Phase 3, raising concerns about ‘slow progress’. However, of the active trials logged on ClinicalTrials.gov at the time of the latest report, 35 were found to be newly registered. The report authors concluded: “The slow progress and lack of agents transitioning from Phase 2 to Phase 3 is concerning, but collective efforts by various stakeholders are being made to accelerate the clinical trial process, with the aim of bringing new therapies to the [Parkinson’s] community sooner.”
Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award
Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…
Study explores predictors of cognitive impairment in Parkinson’s disease
Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.